BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12640556)

  • 1. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
    Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
    Sundaram SK; Freedman NM; Carrasquillo JA; Carson JM; Whatley M; Libutti SK; Sellers D; Bacharach SL
    J Nucl Med; 2004 Aug; 45(8):1328-33. PubMed ID: 15299057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
    Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
    Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
    J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of 18F-Fluoride Kinetics: Evaluation of Simplified Methods.
    Raijmakers P; Temmerman OP; Saridin CP; Heyligers IC; Becking AG; van Lingen A; Lammertsma AA
    J Nucl Med; 2014 Jul; 55(7):1122-7. PubMed ID: 24868107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
    Freedman NM; Sundaram SK; Kurdziel K; Carrasquillo JA; Whatley M; Carson JM; Sellers D; Libutti SK; Yang JC; Bacharach SL
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):46-53. PubMed ID: 12483409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of N-butylscopolamine on SUV in FDG PET of the bowel.
    Sanghera B; Emmott J; Wellsted D; Chambers J; Wong WL
    Ann Nucl Med; 2009 Jul; 23(5):471-8. PubMed ID: 19444552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.
    Cheebsumon P; Velasquez LM; Hoekstra CJ; Hayes W; Kloet RW; Hoetjes NJ; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):832-42. PubMed ID: 21210109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
    Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
    Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different quantitative approaches to 18F-fluoride PET scans.
    Brenner W; Vernon C; Muzi M; Mankoff DA; Link JM; Conrad EU; Eary JF
    J Nucl Med; 2004 Sep; 45(9):1493-500. PubMed ID: 15347716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; HindiƩ E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; EspiƩ M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.